Deer Farms Sought for EHDV2 Vaccine Study


Deer farmers sought to participate in important EHDV2 vaccine study

Vaccine manufacturer Medgene Labs is seeking deer farms to participate in a vaccine study trial for Epizootic Hemorrhagic Disease Virus (EHDV) 2.  The purpose of the study is to provide supporting data for expectation of efficacy and safety of a vaccine to address EHDV2.*  The goal of the study is to accelerate licensing of a safe, effective EHDV2 vaccine.

This study will also help with development of vaccines for EHDV1 and EHDV6 along with vaccines for Bluetongue Virus serotypes.

Depending upon the location of the deer herd, The UF IFAS Cervidae Health Research Initiative (CHeRI) will be playing an evaluative role in the study, qualifying deer farmers and evaluating outcomes.

Study process:

1) Interested deer farmers must contact Medgene Labs directly per contact listed below.  The study will be partitioned into two groups: Florida Farmers and Non-Florida Farmers.

2) Once selected, Medgene Labs will provide deer farmers the vaccine and administration instructions.

3) CHeRI will follow up with Florida-based trial participants via phone calls to check on the health of animals.

4) Farmers will agree to participate in research protocol that will be managed by CHeRI and/or Medgene Labs.  For Florida-based farmers, CHeRI will be providing support visits, including, when necessary, necropsies.

5) Results will be shared through CHeRI and NADeFA.

This study will begin soon—if you are interested, do not delay.

Contact Ashley Swanhorst at Medgene Labs (1-605-692-1268) or to request sign-up for the study.

*The EHDV2 vaccine provided as part of this study will not protect against EHDV1 or EHDV6.

Medgene at NADeFa

Medgene Labs will be presenting (and representing!) at the 2019 North American Deer Farmers Association NADeFA conference!

This year’s event is held in Tulsa, Oklahoma—Medgene is thrilled to get out of the frosty world of South Dakota for a little warmth.  However, the most important aspect of our presence is to share news about our upcoming vaccine for EHDV (Epizootic Hemorrhagic  Disease Virus), available later this year.





Vet cooperation on antimicrobial

Global veterinary organizations issue joint statement against antimicrobial resistance

U.S., Canada, and Europe team up in an effort to make a change internationally

December 7, 2018

As the fight against antimicrobial resistance continues, veterinarians from around the world are uniting to ensure best practice is in place.

Veterinary organizations in Europe and Canada have issued a joint statement[1] with the American Veterinary Medical Association (AVMA) to establish oversight of antimicrobial use, mitigation of antimicrobial resistance, and the continuing availability of critical animal and human medications.

The Joint Statement on Continuous Monitoring of Antimicrobial Use and Antimicrobial Resistance describes strategies to preserve the effectiveness and availability of antimicrobial drugs and safeguard animal welfare, public health, and the environment.

“This joint statement is an important step in recognizing ways we can work together to prevent resistance and ensure antimicrobials continue to be used judiciously in animals,” said AVMA president, John de Jong, DVM.

Some recommendations included in the Canadian Veterinary Medical Association (CVMA), Federation of Veterinarians of Europe (FVE), and AVMA’s statement are:

  • Veterinarians must retain access to effective antimicrobials for therapeutic purposes for animals suffering from a bacterial disease.
  • Medically or critically important antimicrobials should only be administered to animals with the oversight of a licensed veterinarian.
  • Record keeping is essential at the patient or practice level to evaluate antimicrobial treatments.
  • In addition to evaluating individual cases, there also is a need to monitor the overall use of antimicrobials with both companion animals and food production.
  • A global network should be established for surveillance and monitoring of antimicrobial use and resistance.
  • Easily accessible, effective, rapid, and standardized diagnostic susceptibility tests should be available and their results should be obtainable to facilitate evidence-based decisions about antimicrobials.



  1. joint statement:

Source URL: